NCT06493279View on ClinicalTrials.gov

Evaluate the Safety and Efficacy of Intrathecal Injection of RJK002 in Patients With Amyotrophic Lateral Sclerosis

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 24, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

May 2, 2031

Conditions

Amyotrophic Lateral Sclerosis Als

Interventions

DRUG

RJK002 Intrathecal injection

Eligible subjects will receive a single intrathecal administration of investigational product with dose 3E13vg (3ml), 6E13vg(6ml), and 1.2E14 vg(12ml) per person sequentially.

Trial Locations (1)

Unknown

RECRUITING

Peking University Third Hospital, Beijing

All Listed Sponsors

collaborator

Peking University Third Hospital

OTHER

lead

RJK Biopharma Ltd

INDUSTRY